Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy

Sproston, Anthony R; Roberts, Stephen A; Davidson, Susan E; Hunter, Robin D; West, Catharine M L

doi:10.1038/bjc.1995.543

Cited by 21 publications

(17 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Serum SCC-ag has been shown to correlate with the clinical FIGO stage, tumor volume, and risk of lymph node metastasis (Sproston et al 1995;Ngan et al 1996;Hong et al 1998;Takeda et al 2002). The most important clinical correlation for pretreatment serum SCC-ag is its ability to predict clinical outcome and its application in the posttreatment surveillance of patients with cervical cancers.…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer

Pan

Cheng

Zhou

et al. 2011

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Higher pretreatment SUVmax of primary tumor indicated worse prognosis, and the prognosis of patients with higher pretreatment SUVmax plus PLN metastasis was even worse both in patients of squamous cell carcinoma (SCC) and non-SCC of cervix. As for patients with SCC of cervix, higher pretreatment serum SCC-ag not only predicted worse prognosis but also predicted disease recurrence in the posttreatment surveillance.

show abstract

Section: Discussionmentioning

confidence: 98%

“…Serum squamous cell carcinoma antigen (SCC-ag) levels are elevated in 28-88% of patients with squamous cell carcinoma (SCC) and correlate with most predictive factors mentioned above (Nakamura et al 2010;Sproston et al 1995;Ngan et al 1996;Hong et al 1998;Takeda et al 2002).…”

Section: Introductionmentioning

confidence: 95%

The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer

Pan

Cheng

Zhou

et al. 2011

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…This has been highlighted in our own work in a study of pretreatment measurements of serum markers (CA125, SCC, TPA) in carcinomas of the cervix. Although all British Journal of Cancer (1997) Radiosensitivity in cenrix cancer 1189 (Sproston et al, 1995). In the current study with 128 women, the higher patient numbers have now permitted multivariate analyses to be performed.…”

Section: Discussionmentioning

confidence: 99%

The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix

West

Davidson²,

Roberts³

et al. 1997

Br J Cancer

Self Cite

151

View full text Add to dashboard Cite

Summary A study was made of the prognostic value of pretreatment measurements of tumour radiosensitivity (surviving fraction at 2 Gy, SF2) in 128 patients with stage I-Ill carcinomas of the uterine cervix undergoing radiotherapy. The median follow-up time was 47 months. In a univariate analysis stratifying patients according to the median value, radiosensitivity was a significant prognostic factor for overall survival, local control and metastasis-free survival. The 5-year survival rate for tumours with SF2 values below the median was 81% and was significantly greater than the rate of 51% for those with SF2 values above the median. In bivariate analyses, SF2 was shown to be independent of disease stage, tumour grade, patient age, colony-forming efficiency and tumour diameter. In a multivariate analysis, radiosensitivity was the most important variable and, after allowing for this, only stage was a significant independent predictor of treatment outcome. These data indicate that, in carcinoma of the cervix treated with radiotherapy, pretreatment tumour intrinsic radiosensitivity is an important prognostic parameter and contributes to prognosis independently of other established and putative parameters.Keywords: predictive assay; intrinsic radiosensitivity; SF2; cervix cancer; radiotherapy There are considered to be three important radiobiological factors that determine how well a tumour responds to radiotherapy: intrinsic radiosensitivity, hypoxia and proliferation. The clinical relevance of these parameters is currently receiving considerable attention, and studies have been published suggesting the potential of all three as prognostic factors for radiotherapy (West, 1994).In carcinoma of the cervix, our own studies have indicated that tumour radiosensitivity is an important determinant of treatment outcome (West et al, 1991(West et al, , 1993. In this work, radiosensitivity is measured using a soft agar clonogenic assay as surviving fraction after 2 Gy in vitro irradiation (SF2). Some support for our finding has come from work on head and neck tumours, which has shown that radiosensitivity, measured using a growth assay as the initial slope of radiation survival curves (a), significantly influenced patient outcome when a high (above median) value was used to stratify data (Girinsky et al, 1994). Other smaller studies using a variety of assays have also suggested that radiosensitive tumours are more responsive to therapy (Hinkley and Bosanquet, 1992;Ramsay et al, 1992;Vaughan et al, 1993;Shibamoto et al, 1994). Studies that have shown no relationship between tumour radiosensitivity and treatment outcome either involved the establishment of cell lines before assay (Allalunis-Turner et al, 1992;Schwartz et al, 1992;Taghian et al, 1993) or treatment with surgery plus radiotherapy (Brock et al, 1992), both of which may be confounding influences.This paper forms an update of a previous study (West et al, 1993) Correspondence to: C West 88 patients. In this report, for the first time, a multivariate analysis has been ...

show abstract

“…1). Sproston et al [26] concluded that serum CA 125 is better than SCC antigen at predicting recurrence-free survival in patients treated with radiotherapy. Their study, however, was not limited to patients with a localized disease.…”

Section: Prognosismentioning

confidence: 99%

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

et al. 1998

View full text Add to dashboard Cite

A review is given of the clinical use and interpretation of serum tumor marker levels during the treatment of patients with cancer of the uterine cervix. Pretreatment serum squamous cell carcinoma (SCC) antigen provides a new prognostic factor in early stage squamous cell carcinoma of the uterine cervix. Elevated serum values of SCC antigen at the time of diagnosis of stage IB and IIA cervical cancer indicate a 3 × increased risk of tumor recurrence, independent of tumor diameter, grade or the presence of lymph node metastases. High pretreatment SCC antigen levels could therefore be used to select ‘high-risk’ patients for adjuvant therapy. Measurement of the serum SCC antigen levels provides a means of monitoring the effect of therapy. During the postoperative follow-up of patients with localized cancer of the uterine cervix the measurement of SCC antigen can lead to the early detection of recurrent disease when curative therapy is still an option. The profile of serum SCC antigen parallels the response to radiotherapy and provides a way of evaluating the effectiveness of chemotherapy. Serial measurements after surgery and during radio- and chemotherapy demonstrate that SCC antigen is a more sensitive marker for recognizing tumor progression or recurrence than CYFRA-21.1, TPS or CEA. When following up patients with a pure adenocarcinoma of the cervix measurements of serum CA 125 and CEA are preferred over SCC antigen measurements.

show abstract

Serum tumour markers in carcinoma of the uterine cervix and outcome following radiotherapy

Cited by 21 publications

References 8 publications

The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer

The SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) and serum squamous cell carcinoma antigen (SCC-ag) function as prognostic biomarkers in patients with primary cervical cancer

The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix

The Clinical Value of Squamous Cell Carcinoma Antigen in Cancer of the Uterine Cervix

Contact Info

Product

Resources

About